4.8644
6.16%
0.1544
Schlusskurs vom Vortag:
$4.71
Offen:
$4.71
24-Stunden-Volumen:
9,723
Relative Volume:
0.34
Marktkapitalisierung:
$25.19M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.35M
KGV:
-2.0439
EPS:
-2.38
Netto-Cashflow:
$-11.88M
1W Leistung:
-4.03%
1M Leistung:
-10.07%
6M Leistung:
-23.90%
1J Leistung:
+99.20%
Lipocine Inc Stock (LPCN) Company Profile
Firmenname
Lipocine Inc
Sektor
Branche
Telefon
801 994 7383
Adresse
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Vergleichen Sie LPCN mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
LPCN | 4.91 | 25.19M | 0 | -16.35M | -11.88M | -2.38 |
VRTX | 449.07 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 748.73 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 587.28 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 247.66 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 106.61 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2021-06-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
2020-12-10 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
2018-01-12 | Bestätigt | H.C. Wainwright | Buy |
2018-01-11 | Herabstufung | Canaccord Genuity | Buy → Hold |
2017-12-08 | Fortgesetzt | H.C. Wainwright | Buy |
2016-10-07 | Eingeleitet | H.C. Wainwright | Buy |
2015-07-22 | Eingeleitet | ROTH Capital | Buy |
2015-06-23 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Lipocine Inc Aktie (LPCN) Neueste Nachrichten
Lipocine's LPCN 1148 Shows Breakthrough Results in Liver Disease Clinical Trial | LPCN Stock News - StockTitan
Lipocine (NASDAQ:LPCN) Announces Financial Results for the Quarter Ended September 30, 2024 - Defense World
When the Price of (LPCN) Talks, People Listen - Stock Traders Daily
Lipocine: Q3 Earnings Snapshot - CT Insider
Lipocine Inc. (LPCN) Quarterly 10-Q Report - Quartz
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024 - PR Newswire
Lipocine Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Lipocine (NASDAQ:LPCN) Presents Positive Data on LPCN 2401 at Obesity Society Conference - Defense World
Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference - GuruFocus.com
Lipocine inks deal to bring TLANDO to South Korea - Investing.com
Lipocine Partners With SPC Korea For TLANDO In South Korea - Contract Pharma
Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea - Morningstar
Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study i - GuruFocus.com
Trading (LPCN) With Integrated Risk Controls - Stock Traders Daily
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1 - GuruFocus.com
Lipocine Announces Completion of Dosing in Pivotal Study of Post - GuruFocus.com
(LPCN) Trading Signals - Stock Traders Daily
Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Bod - GuruFocus.com
Lipocine reports promising oral brexanolone study results By Investing.com - Investing.com Australia
Lipocine reports promising oral brexanolone study results - Investing.com India
Lipocine Enters Exclusive Supply And Distribution Agreement With Pharmalink - Contract Pharma
Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results - PR Newswire
Lipocine signs supply and distribution agreement with Pharmalink for Tlando - Yahoo Finance
Lipocine partners with Pharmalink for GCC distribution of TLANDO - Investing.com
Lipocine partners with Pharmalink for GCC distribution of TLANDO By Investing.com - Investing.com Nigeria
Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries - PR Newswire
Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024 - Citizentribune
Alliance Global Partners Initiates Coverage on Lipocine (NASDAQ:LPCN) - Defense World
Lipocine (NASDAQ:LPCN) Upgraded to Buy at StockNews.com - Defense World
‘Lubber Pandhu also has strong emotions beyond cricket’ - DTNEXT
Louisiana-Pacific director sells $245,750 in company stock By Investing.com - Investing.com Canada
PLRX’s 52-Week Rollercoaster: From $10.29 to $19.62 – What’s Next for Investors? - The InvestChronicle
Health Check: Paradigm receives FDA guidance on proposed trial for dodgy knees - Stockhead
Pliant Therapeutics (NASDAQ:PLRX) Sees Large Volume Increase - MarketBeat
Liquidia Corp [LQDA] Investment Guide: What You Need to Know - Knox Daily
MediPharm Labs Corp. - Baystreet.ca
A stock that deserves closer examination: Lipella Pharmaceuticals Inc (LIPO) - US Post News
PLRX’s latest rating updates from top analysts. - Knox Daily
Labcorp Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Pliant Therapeutics (NASDAQ:PLRX) Shares Gap Up to $12.00 - MarketBeat
Prudential PLC Sells 7,956 Shares of Laboratory Co. of America Holdings (NYSE:LH) - MarketBeat
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Research Analysts Set Expectations for Pliant Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:PLRX) - Defense World
Lipocine Inc. filed SEC Form 8-K: Financial Statements and Exhibits - Quantisnow
Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek® - Kilgore News Herald
Lipocine (NASDAQ:LPCN) Downgraded by StockNews.com to “Hold” - Defense World
Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference – Company Announcement - Financial Times
Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Sarcopenia Market to Grow Positively at a Paltry CAGR During - openPR
StockNews.com Lowers Lipocine (NASDAQ:LPCN) to Hold - Defense World
Lipocine (NASDAQ:LPCN) Raised to Buy at StockNews.com - Defense World
Finanzdaten der Lipocine Inc-Aktie (LPCN)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):